Restatement of the Consolidated Financial Statements Consolidated Statements of Cash Flows (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010		Dec. 31, 2012 Adjustments for New Accounting Pronouncement [Member]	Dec. 31, 2011 Adjustments for New Accounting Pronouncement [Member]	Dec. 31, 2010 Adjustments for New Accounting Pronouncement [Member]	Dec. 31, 2012 Scenario, Previously Reported [Member]	Dec. 31, 2011 Scenario, Previously Reported [Member]	Dec. 31, 2010 Scenario, Previously Reported [Member]	Dec. 31, 2012 Immaterial Correction of Prior Period Error [Member]	Dec. 31, 2011 Immaterial Correction of Prior Period Error [Member]	Dec. 31, 2012 Restatement Adjustment [Member]	Dec. 31, 2011 Restatement Adjustment [Member]	Dec. 31, 2010 Restatement Adjustment [Member]	Dec. 31, 2012 Scenario, Actual [Member]	Dec. 31, 2011 Scenario, Actual [Member]	Dec. 31, 2010 Scenario, Actual [Member]
Operating Activities
Net Income	$ 15,165	$ 13,509	$ 15,194			$ (506)	$ (1,009)		$ 14,514	$ 16,203		$ 0		$ (499)	$ 0		$ 13,509	$ 15,194
Adjustments to reconcile net income to net cash flows (used in) provided by operating activities:
Change in deferred acquisition costs	(3,692)					778	1,553		3,223	(5,754)		0		(93)			3,908	(4,201)
Depreciation and amortization	8,886					0	0		8,029	4,628		0		0			8,029	4,628
Deferred income tax expense	4,252	1,721	4,337			(272)	(544)		3,397	4,881		(1,071)		(333)			1,721	4,337
Net realized investment (gains) losses	(3)					0	0		(4,193)	(650)		0		0			(4,193)	(650)
Loss on sale of subsidiary	0	477				0			477			0		0			477	0
Stock-based compensation expense	1,044					0	0		763	176		0		0			763	176
Direct stock awards to employees	(49)																0	0
Amortization of premiums and accretions of discounts on investments	1,283					0	0		609	348		0		0			609	348
Non-controlling interests	72					0	0		(170)	(772)		0		0			(170)	(772)
Change in allowance for doubtful accounts	(90)					0	0		(31)	(30)		0		0			(31)	(30)
Increase (Decrease) in Operating Capital:
Accrued investment income	(306)					0	0		(16)	30		0		0			(16)	30
Accounts and premiums receivable, net	(4,933)					0	0		(898)	3,808		0		0			(898)	3,808
Other receivables	(4,139)					0	0		(1,430)	1,884		(339)		0			(1,769)	1,884
Reinsurance receivables	(9,248)					0	0		(5,181)	4,416		0		0			(5,181)	4,416
Income Taxes Receivable	(3,628)					0	0		818	(818)		0		0			818	(818)
Other assets	865					0	0		(389)	(1,600)		0		0			(389)	(1,600)
Unpaid claims	248					0	0		(315)	(3,459)		0		0			(315)	(3,459)
Unearned premiums	7,971					0	0		14,373	(5,222)		0		0			14,373	(5,222)
Policyholder account balances	(2,017)					0	0		(45)	0		0		0			(45)	0
Accrued expenses, accounts payable and other liabilities	20,190					0	0		(14,909)	(7,379)		0		0			(14,909)	(7,379)
Income Taxes Payable	(1,344)					0	0		1,344	(769)		0		0			1,344	(769)
Deferred revenue	1,363					0	0		(7,394)	3,181		0		925			(6,469)	3,181
Net cash flows provided by (used in) operating activities	31,988				0		0	12,576		13,102	(1,410)		0			11,166	11,166	13,102
Investing Activities:
Proceeds from maturities, calls and prepayments of available-for-sale investments	11,138					0	0		9,691	12,114		0		0			9,691	12,114
Proceeds from sales of available-for-sale investments	8,364	62,300	8,769			0	0		62,300	8,769		0		0			62,300	8,769
Net change in short-term investments	100					0	0		100	50		0		0			100	50
Purchases of available-for-sale investments	(40,445)					0	0		(63,557)	(24,047)		1,410		0			(62,147)	(24,047)
Purchases of property and equipment	(5,830)					0	0		(6,280)	(9,191)		0		0			(6,280)	(9,191)
Net paid for acquisitions of subsidiaries, net of cash received	(21,820)					0	0		(49,873)	(20,548)		0		0			(49,873)	(20,548)
Sale of subsidiary, net of cash paid	0					0			(153)			0		0			(153)	0
Proceeds from notes receivable	(1,346)					0	0		(975)	684		0		0			(975)	684
Change in restricted cash, net of restricted cash received from acquisitions	(9,452)					0	0		1,542	2,368		0		0			1,542	2,368
Net cash flows (used in) provided by investing activities	(59,291)				0		0	(47,205)		(29,801)	1,410		0			(45,795)	(45,795)	(29,801)
Financing activities
Repayments of notes payable	(130,450)					0	0		(74,263)	(20,000)		0		0			(74,263)	(20,000)
Proceeds from notes payable	146,888					0	0		110,550	25,226		0		0			110,550	25,226
Payments of Debt Issuance Costs	1,692						0			1,379							0	1,379
Proceeds from Issuance Initial Public Offering	0						0			40,703							0	40,703
Payments for intial public offering costs	0					0			(826)			0		0			(826)	0
Payments on redeemable preferred stock	0					0	0		(11,040)	(500)		0		0			(11,040)	(500)
Payments of Capital Distribution	0						0			14,105							0	14,105
Net proceeds from exercise of stock options	20					0	0		607	117		0		0			607	117
Excess tax benefits from stock-based compensation	0					0	0		45	86		0		0			45	86
Purchase of treasury stock	(3,923)					0			(2,552)			0		0			(2,552)	0
Net proceeds received from stock issued in the Employee Stock Purchase Plan	330	100	0	[1]		0			58			0		0			58	0
Net cash flows (used in) provided by financing activities	11,173					0	0		22,579	30,148		0		0			22,579	30,148
Net (decrease) increase in cash and cash equivalents	(16,130)					0	0		(12,050)	13,449		0		0			(12,050)	13,449
Cash and cash equivalents, beginning of period	31,339				0	0	0	31,339	43,389	29,940	0	0	0	0		31,339	43,389	29,940
Cash and cash equivalents, end of period	$ 15,209	$ 31,339				$ 0	$ 0		$ 31,339	$ 43,389		$ 0		$ 0	$ 0		$ 31,339	$ 43,389

[1] (1) The Company's ESPP began open enrollment in July 2011.